TY - JOUR
T1 - Transcatheter Mitral Valve Replacement with Intrepid
AU - McCarthy, Patrick M.
AU - Kislitsina, Olga N.
AU - Malaisrie, Sukit Chris
AU - Davidson, Charles J.
N1 - Funding Information:
Disclosure Statement: Dr P.M. McCarthy: Edwards Lifescience: consultant and royalties; Abbott Vascular: consultant and advisory board; Medtronic; unpaid member of the Apollo Trial Steering Committee. Dr O.N. Kislitsina: None. Dr S.C. Malaisrie: Edwards Lifescience: consultant, speaker; Medtronic, consultant; Abbott, speaker. Dr C.J. Davidson: Edwards Lifesciences: grant support.
Funding Information:
Disclosure Statement: Dr P.M. McCarthy: Edwards Lifescience: consultant and royalties; Abbott Vascular: consultant and advisory board; Medtronic; unpaid member of the Apollo Trial Steering Committee. Dr O.N. Kislitsina: None. Dr S.C. Malaisrie: Edwards Lifescience: consultant, speaker; Medtronic, consultant; Abbott, speaker. Dr C.J. Davidson: Edwards Lifesciences: grant support. Disclosure Statement: Dr P.M. McCarthy: Edwards Lifescience: consultant and royalties; Abbott Vascular: consultant and advisory board; Medtronic; unpaid member of the Apollo Trial Steering Committee. Dr O.N. Kislitsina: None. Dr S.C. Malaisrie: Edwards Lifescience: consultant, speaker; Medtronic, consultant; Abbott, speaker. Dr C.J. Davidson: Edwards Lifesciences: grant support.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - Transcatheter mitral valve replacement with the Intrepid device is intended for patients who need mitral valve replacement and who are at an increased risk for conventional surgery. The early published results of the early feasibility trial are reviewed as well as device design and the implant procedure. The Apollo trial is reviewed: a randomized trial of the Intrepid device versus conventional surgery including a single arm study for inoperable patients. The mitral valve structure, pathophysiology, and postimplant physiology pose unique hurdles for any transcatheter implant.
AB - Transcatheter mitral valve replacement with the Intrepid device is intended for patients who need mitral valve replacement and who are at an increased risk for conventional surgery. The early published results of the early feasibility trial are reviewed as well as device design and the implant procedure. The Apollo trial is reviewed: a randomized trial of the Intrepid device versus conventional surgery including a single arm study for inoperable patients. The mitral valve structure, pathophysiology, and postimplant physiology pose unique hurdles for any transcatheter implant.
KW - Apollo trial
KW - Mitral regurgitation
KW - Mitral valve
KW - Transcatheter mitral valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85063893495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063893495&partnerID=8YFLogxK
U2 - 10.1016/j.iccl.2019.02.002
DO - 10.1016/j.iccl.2019.02.002
M3 - Review article
C2 - 31078184
AN - SCOPUS:85063893495
SN - 2211-7458
VL - 8
SP - 287
EP - 294
JO - Interventional Cardiology Clinics
JF - Interventional Cardiology Clinics
IS - 3
ER -